Articles Mentioning Biotechnology Stocks

Results 1 - 10 of 377 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology

Investing | March 23, 2015

This Market Could Grow 6250% in 10 Years

With the regulatory pathway cleared, the biosimilars market is poised to turn into a gold mine, growing up to 6,250% in 10 years. Here's where to stake your claim.

Investing | March 22, 2015

3 Things You Need to Know About Achillion Pharmaceuticals Inc.

Achillion Pharmaceuticals has a big opportunity in hepatitis C, but it also faces some risks.

Investing | March 21, 2015

Dividend Stocks: 2 to Avoid, 1 to Buy

Motley Fool contributor Todd Campbell offers up two dividend-paying healthcare stocks to avoid and one that could be a good buy for long-term income investors.

Investing | March 21, 2015

Drug Spending Is Soaring: 3 Takeaways You Can't Miss

Drug spending in the U.S. showed solid growth in several major indications; here’s what it means to you.

Investing | March 19, 2015

This Exciting Biotech Isn't Built to Last

Acadia Pharmaceuticals' Parkinson's disease drug was guaranteed a speedy review and the attention of top FDA officials. So why did this company's stock recently tank so rapidly? There's a cautionary tale here for all biotech investors.

Investing | March 15, 2015

Should Gilead Sciences Inc.’s Slowing Growth Concern Investors?

Gilead Sciences has been one of the fastest-growing biotech companies over the past few years. The company's rocket-like growth trajectory, though, is expected to start slowing starting this year. Should investors be concerned?

Investing | March 09, 2015

Why AbbVie Inc.'s $21 Billion Deal Had To Happen

AbbVie Inc has agreed to pay $21 billion to acquire Pharmacyclics, Inc.

Investing | February 21, 2015

Pssst... Pfizer Just Told Investors That This is the Next Big Thing

Pfizer Inc.'s acquisition of Hospira could signal that investors should embrace biosimilar drugmakers.

Investing | February 20, 2015

$20 Billion Market: What’s the Best Stock to Buy?

Three drug companies to watch as biologics come off patent and investors anticipate a biosimilar boom -- here's what you need to know.

Investing | February 18, 2015

Is Gilead Sciences Inc. Stock Cheap Now?

Gilead Sciences has fallen by double-digits from its 52-week high. Is the stock now too cheap to ignore?

Results 1 - 10 of 377 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology